DermiSphere

德米斯菲

™

商标

, the first of its kind

，同类中的第一个

hydrogel Dermal Regeneration Template, attracts world-class financial and strategic investors as clinical momentum accelerates

水凝胶真皮再生模板随着临床势头加速，吸引世界级财务和战略投资者

NEW YORK

纽约

,

，

June 10, 2026

2026年6月10日

/PRNewswire/ -- FesariusTherapeutics, a commercial-stage medical technology company reimagining dermal repair, today announced the close of an oversubscribed $20 million Series A financing round. The round was anchored by Jefferson Life Sciences (JLS) and joined by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.), Empire State Development's NY Ventures, and the American Society of Plastic Surgeons (ASPS), marking its inaugural institutional investment.

/美通社/ -- 重塑皮肤修复领域的商业化阶段医疗科技公司Fesarius Therapeutics今日宣布，已完成超额认购的2000万美元A轮融资。本轮融资由Jefferson Life Sciences（JLS）领投，强生公司（通过其企业风险投资机构Johnson & Johnson Innovation – JJDC, Inc.）、纽约州经济发展局旗下的NY Ventures以及美国整形外科医师协会（ASPS）跟投，其中后者标志着其首次机构投资。

The company's flagship product, DermiSphere.

该公司的旗舰产品 DermiSphere。

™

商标

, which is the first of its kind hydrogel Dermal Regeneration Template (hDRT) on the U.S. market, was cleared by FDA in 2025 for managing various wound types

作为美国市场上首款此类水凝胶真皮再生模板（hDRT），于2025年获得美国食品药品监督管理局（FDA）批准，用于管理各种类型的伤口

1

1

.

。

The financing marks a significant milestone for Fesarius, validating its technology in the clinic, building commercial momentum across U.S. hospital systems, and positioning the company for its next phase of growth. With this capital, Fesarius will build on its existing commercial presence across multiple U.S.

此次融资为Fesarius标志着一个重要的里程碑，验证了其技术在临床中的应用，在美国医院系统中建立了商业势头，并使公司处于下一阶段的成长位置。借助这笔资金，Fesarius将在其现有的美国多个地区的商业存在基础上进一步发展。

hospital systems by accelerating its commercial infrastructure, including additional direct field representatives to broaden national market coverage, pursue Breakthrough Device Designation with expanded reimbursement pathways and advance the clinical trial for its OneStep procedure - the placement of DermiSphere.

通过加速其商业基础设施建设，包括增加更多直接驻外代表以扩大全国市场覆盖范围；积极争取突破性设备认定并拓展报销渠道；推进 OneStep 手术（即 DermiSphere 植入术）的临床试验。

™

商标

and a skin graft in a single surgery, which is the subject of a future application for label expansion. This use of the device has the potential to eliminate the second surgery currently required by the current standard of care, which could reduce patient recovery time, pain, and total cost of care..

并在单次手术中完成植皮，这将是未来申请扩大适应症范围的主题。该设备的这种应用有望消除当前标准治疗所需的第二次手术，从而缩短患者恢复时间、减轻疼痛并降低总体治疗成本。

The $1.6 billion U.S. market for dermal regeneration has seen virtually no innovation over the last 30 years. As the first of its kind hDRT, DermiSphere's

价值16亿美元的美国皮肤再生市场在过去30年中几乎没有任何创新。作为首款同类人源真皮再生模板（hDRT），DermiSphere的

™

商标

novel dual-density collagen microarchitecture is designed to drive faster cellular infiltration and vascularization to support the body's natural wound healing process.

新型双密度胶原微结构旨在促进更快的细胞浸润和血管化，以支持机体的自然伤口愈合过程。

'We are excited to support Fesarius' vision to revolutionize deep wound care and help improve outcomes for millions of patients that require skin grafts. DermiSphere

“我们很高兴支持 Fesarius 的愿景，彻底革新深度伤口护理，并帮助改善数百万需要皮肤移植患者的治疗结果。DermiSphere”

™

商标

is already making a difference for patients. We believe Fesarius is positioned to redefine the category.' - Laura Lande-Diner, Managing Partner, Jefferson Life Sciences

“已经为患者带来显著改善。我们相信，Fesarius 有望重新定义这一领域。”——杰斐逊生命科学管理合伙人劳拉·兰德-迪纳

'New York is building one of the nation's most dynamic life sciences ecosystems, and companies like Fesarius are exactly why. DermiSphere

纽约正在打造全美最具活力的生命科学生态系统之一，而像Fesarius这样的公司正是其成功的关键。DermiSphere

™

商标

is the kind of innovation we want developed and scaled here, with the potential to dramatically improve outcomes for patients while creating high-quality jobs and economic opportunity across the state. Through NY Ventures, we're proud to invest in New York innovators defining the future of medicine.' - Jennifer Tegan, Managing Director, New York Ventures, Empire State Development.

“这正是我们希望在本州培育并推广的创新类型，它有望显著改善患者疗效，同时在全州创造高质量的就业机会和经济机遇。通过纽约风险投资公司（NY Ventures），我们很自豪能够投资于那些正在定义医学未来的纽约创新者。”——詹妮弗·蒂根，纽约风险投资公司董事总经理，帝国州发展公司

'This inaugural investment in Fesarius marks a new chapter for ASPS Ventures, one where we move from advocates to active partners in advancing technologies developed by our members. We are proud to play a role in helping to bring this technology to the patients who need it most.' - Michael Costelloe, Executive Vice President of the American Society of Plastic Surgeons and CEO of ASPS Ventures, LLC.

“对 Fesarius 的这笔首创性投资标志着 ASPS Ventures 开启了新篇章，我们将从倡导者转变为积极合作伙伴，推动由我们的会员开发的技术进步。我们自豪地能够发挥作用，帮助将这项技术带给最需要的患者。”——美国整形外科医师协会执行副总裁兼 ASPS Ventures, LLC 首席执行官迈克尔·科斯特洛

'DermiSphere

德米斯菲尔

™

商标

is creating a new frontier in dermal repair by fundamentally changing how surgeons treat seriously destructive skin loss. Patients are experiencing promising outcomes already and this financing accelerates our clinical programs, expands our commercial reach, and ensures that every patient can access the truly remarkable outcomes we are seeing with DermiSphere.

通过从根本上改变外科医生治疗严重破坏性皮肤缺损的方式，我们正在开创皮肤修复的新前沿。患者已经展现出令人鼓舞的治疗效果，而此次融资将加速我们的临床项目，扩大我们的商业覆盖范围，并确保每位患者都能获得我们在DermiSphere中见证的卓越疗效。

™

商标

h

h

DRT.' - Tom Roueche, President and CEO, FesariusTherapeutics

DRT。”——Fesarius Therapeutics 总裁兼首席执行官 Tom Roueche

About FesariusTherapeutics

关于 FesariusTherapeutics

FesariusTherapeutics is a commercial-stage medical technology company reimagining dermal repair. Its flagship product, DermiSphere

Fesarius Therapeutics 是一家处于商业化阶段的医疗技术公司，致力于重塑皮肤修复领域。其旗舰产品 DermiSphere

™

商标

is the first of its kind hydrogel Dermal Regeneration Template (hDRT), with a patented, dual-density collagen microarchitecture that is designed to facilitate cellular integration and vascularization to support wound healing. The device is 510(k)-cleared by FDA for wound management and commercially active across multiple U.S.

是首款水凝胶真皮再生模板（hDRT），拥有专利的双密度胶原微结构，旨在促进细胞整合和血管化，以支持伤口愈合。该器械已获得美国食品药品监督管理局（FDA）510(k)许可，用于伤口管理，并在美国多个地区实现商业化应用。

hospital systems. The company is headquartered in New York and is advancing toward a pivotal clinical trial to support a planned future label expansion and Breakthrough Device Designation. For more information, visit fesariustherapeutics.com..

医院系统。公司总部位于纽约，正积极推进一项关键性临床试验，以支持计划中的未来适应症扩展及突破性设备认定。欲了解更多信息，请访问 fesariustherapeutics.com。

About Jefferson Life Sciences

关于杰斐逊生命科学

Jefferson Life Sciences, part of Jefferson River Capital, is an investment firm committed to advancing transformative innovations in medicine. The firm brings versatile investment structures and a long-term view to support companies across their full lifecycle—from early development through commercialization, in both private and public settings.

杰斐逊生命科学（Jefferson Life Sciences）是杰斐逊河资本（Jefferson River Capital）旗下的一家投资公司，致力于推动医学领域的变革性创新。该公司提供灵活多样的投资架构，并秉持长期视角，支持企业在私有和公共市场环境中完成从早期开发到商业化的全生命周期发展。

By combining intelligent financing with deep operational expertise, we help turn bold scientific ideas into meaningful therapeutic solutions for patients in need..

通过将智能融资与深厚的运营专业知识相结合，我们帮助将大胆的科学理念转化为满足患者需求的重要治疗解决方案。

About Empire State Development

关于纽约州帝国大厦发展公司

Empire State Development is New York's chief economic development agency, and promotes business growth, job creation, and greater economic opportunity throughout the state. With offices in each of the state's 10 regions, ESD oversees the

纽约州经济发展局是纽约州主要的经济发展机构，致力于促进全州范围内的业务增长、就业创造和更多经济机会。ESD在该州10个地区均设有办事处，负责监督

Regional Economic Development Councils

区域经济发展委员会

, supports broadband equity through the ConnectALL office, and is growing the workforce of tomorrow through the Office of Strategic Workforce Development. The agency engages with emerging and next generation industries like clean energy and semiconductor manufacturing looking to grow in New York State, operates a network of assistance centers to help small businesses grow and succeed, and promotes the state's world class tourism destinations through I LOVE NY.

通过ConnectALL办公室支持宽带公平，并通过战略劳动力发展办公室培养未来的劳动力。该机构与清洁能源和半导体制造等希望在纽约州发展的新兴及下一代产业开展合作，运营一个援助中心网络以帮助小企业成长并取得成功，并通过“我爱纽约”（I LOVE NY）项目推广该州世界级的旅游目的地。

For more information, please visit .

更多信息，请访问。

esd.ny.gov

esd.ny.gov

, and connect with ESD on

，并与ESD建立联系

LinkedIn

领英

,

，

Facebook

脸书

, and

，和

X

X

.

。

About Empire State Development's New York Ventures

关于纽约州经济发展局的纽约创投项目

New York Ventures, a division of Empire State Development, strategically invests in high-growth companies that leverage technology to solve critical challenges across New York State. Through targeted investments and partnerships, the division expands access to venture capital for underserved regions and traditionally underrepresented entrepreneurs, including women and minority founders and fund managers.

纽约创投（New York Ventures）是纽约州帝国州发展公司（Empire State Development）旗下的一个部门，战略性地投资于那些利用技术解决纽约州关键挑战的高增长公司。通过有针对性的投资和合作伙伴关系，该部门扩大了风险资本在服务不足地区以及传统上代表性不足的创业者（包括女性创始人、少数族裔创始人和基金管理人）中的可及性。

By bridging public and private sector resources, NY Ventures is building a dynamic, inclusive startup ecosystem that drives innovation throughout the state..

通过整合公共和私营部门的资源，NY Ventures 正在构建一个充满活力、包容性的初创企业生态系统，推动全州的创新。

About the American Society of Plastic Surgeons and ASPS Ventures, LLC

关于美国整形外科医师协会及 ASPS Ventures, LLC

The American Society of Plastic Surgeons (ASPS), founded in 1931, is the largest organization of board-certified plastic surgeons in the world. Representing more than 11,000 physician members globally, the society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS Ventures, LLC, is the strategic investment arm of the American Society of Plastic Surgeons.

美国整形外科医师协会（ASPS）成立于1931年，是全球规模最大的经委员会认证的整形外科医师组织。该协会在全球拥有超过11,000名医师会员，被公认为美容与重建整形外科领域的权威机构和信息来源。ASPS Ventures, LLC 是美国整形外科医师协会的战略投资部门。

The organization invests in emerging technologies across medtech, regenerative medicine, robotics and diagnostics that have the potential to improve patient outcomes and advance the future of plastic and reconstructive surgery. The ASPS Ventures leadership team includes some of the most influential surgeons and innovators in the specialty who focused on supporting companies developing innovative solutions for unmet clinical needs..

该组织投资于医疗科技、再生医学、机器人技术和诊断领域的新兴技术，这些技术有望改善患者预后并推动整形与重建外科的未来发展。ASPS Ventures 的领导团队包括该专业领域内一些最具影响力的外科医生和创新者，他们致力于支持那些开发创新解决方案以满足未竟临床需求的公司。

Media Contact

媒体联系人

Jennifer Hanley

詹妮弗·汉利

Communications, FesariusTherapeutics

通讯，费萨里乌斯治疗公司

347-819-0402

347-819-0402

1

1

DermiSphere

德米斯菲尔

™

商标

received FDA 510(k) clearance (K241904) in January 2025. Full indications for use are available in the public 510(k) summary at:

于2025年1月获得美国食品药品监督管理局（FDA）510(k)许可（K241904）。完整的适用范围详见以下网址的公开510(k)摘要：

https://www.accessdata.fda.gov/cdrh_docs/pdf24/K241904.pdf

https://www.accessdata.fda.gov/cdrh_docs/pdf24/K241904.pdf

SOURCE FesariusTherapeutics, Inc

来源：Fesarius Therapeutics, Inc.

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示